

Research & Development – 6 monthly update 6 November 2019

Three wavy lines in blue, green, and pink/magenta colors that sweep across the bottom of the page.

Agenda Item No: 6.5

Trust Board Report

Meeting Date:	6 th November 2019
Title:	Research & Development – 6 monthly update.
Action Requested:	Receive
For the attention of the Board	<p>This report reflects R&D performance since April 2019.</p> <p><u>Key achievements:</u></p> <ul style="list-style-type: none"> • A total of 3055 participants have been recruited into research studies across the Trust to date in 19/20. • 3023 participants have been recruited into Portfolio studies*. This is 93% against the annual target set by the CRNWM (3236). • The R&D Directorate continues to provide alternatives to existing patient care, treatment and choice. • Research activity across a broad range of clinical specialties – not reliant on one study for recruitment. • Continued high ratings from external study monitors. • CRN: West Midlands core funding of £982,367 allocated, £51k reduction on 2018/19 allocation. • The Directorate continues to manage delivery of research in spite of a reduction in core funding, necessitating ongoing skill mix review.
Assure	<ul style="list-style-type: none"> • Performance against NIHR HLO1 and HLO9 on target • Full allocation of CRN WM funding – no underspend reported • Appropriate governance processes in place • R&D Directorate working with Trust Volunteer service to develop PPI.
Advise	<ul style="list-style-type: none"> • Performance against HLO2 a/b below target. If target is not met, this will result in a reduced CRN WM funding allocation for 2010/21.
Author + Contact Details:	Tel 01902 694218 Email jamescotton@nhs.net
Links to Trust Strategic Objectives	<ol style="list-style-type: none"> 1. Create a culture of compassion, safety and quality 2. Proactively seek opportunities to develop our services 3. To have an effective and well integrated local health and care system that operates efficiently 4. Attract, retain and develop our staff, and improve employee engagement 5. Maintain financial health – Appropriate investment to patient services 6. Be in the top 25% of all key performance indicators
Resource Implications:	None
Report Data Caveats	This is a standard report using the previous month's data. It may be subject to cleansing and revision.

CQC Domains	<p>Safe: patients, staff and the public are protected from abuse and avoidable harm.</p> <p>Effective: care, treatment and support achieves good outcomes, helping people maintain quality of life and is based on the best available evidence.</p> <p>Caring: staff involve and treat everyone with compassion, kindness, dignity and respect.</p> <p>Responsive: services are organised so that they meet people's needs.</p> <p>Well-led: the leadership, management and governance of the organisation make sure it's providing high-quality care that's based around individual needs, that it encourages learning and innovation, and that it promotes an open and fair culture.</p>
Equality and Diversity Impact	None
Risks: BAF/ TRR	None
Risk: Appetite	None
Public or Private:	Public
NHS Constitution:	<p>In determining this matter, the Board should have regard to the Core principles contained in the Constitution of:</p> <ul style="list-style-type: none"> • Equality of treatment and access to services • High standards of excellence and professionalism • Service user preferences • Cross community working • Best Value • Accountability through local influence and scrutiny

Brief/Executive Report Details					
1	<p>NIHR CRN WM Performance Targets (RWT)</p> <p>1.1 <u>NIHR High Level Objective (HLO) 1 – Increase the number of participants recruited into NIHR CRN Portfolio studies.</u></p> <p>Table (a) provides study recruitment for the Trust into NIHR Portfolio studies during 19/20.</p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th style="text-align: center;">No. of participants recruited to date 2019-20</th> <th style="text-align: center;">% Recruitment against Trust target (3236)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">3023</td> <td style="text-align: center;">93%</td> </tr> </tbody> </table> <p>RWT currently has 7 recruiting studies led by Trust researchers adopted onto the NIHR Portfolio.</p> <p>1.2 <u>NIHR HLO 2 – Increase the proportion of studies recruiting to time and target.</u></p> <p>Of the 14 studies that have closed to date in 2019/20:</p> <p>(a) 25% of commercial studies and</p> <p>(b) 60% of non-commercial studies recruited to time and target.</p> <p>The target for this indicator is 80%. Achievement of this target is a priority for this year as this will impact on next years CRN funding allocation. Work ongoing to focus on recruitment into those studies due to close within the year.</p> <p>1.3 <u>NIHR HLO 9 – No. of days between 'date site selected' to 'date of first recruit'</u></p>	No. of participants recruited to date 2019-20	% Recruitment against Trust target (3236)	3023	93%
No. of participants recruited to date 2019-20	% Recruitment against Trust target (3236)				
3023	93%				

This indicator is measured only for studies recruiting their first participant in the current financial year.

	Target Median Days	Actual Median Days	No. of studies
Commercial	80	48	4
Non-Commercial	62	31	2

New appointments and a review of the study set-up process have resulted in significant improvements compared to 2018/19 performance. 51 new studies (16 commercial) have been confirmed at RWT since 1st April 19 and 334 study amendments have been processed.

2 Overall Research Performance

2.1 Overall research recruitment and activity across the Trust for Qtrs 1-2 2019/20 is given in table (b) below and further detailed in Appendix 1.

Table (b) – All Study Recruitment

Study Category	Recruitment 19/20
Portfolio – non-commercial	2950
Portfolio – commercial	73
Non-commercial (other)	32
Commercial (direct)	0
Total	3055

3 Finance

3.1 2019/20 Research Funding

The R&D Directorate has received the following funding to support Trust research activity during 19/20:

CRN: West Midlands Allocation

- Core Funding	£982,367
- Strategic Funding	£81,726

This represents a £51k decrease in core funding from 18/19.

All core funding has been allocated, with a breakeven position reported at Qtr 2.

Strategic Funding has been used to support Cardiology and Surgical research. Prior to this year, there was limited research activity within the surgical specialty, however this has changed in 19/20 with 4 studies opened since April 2019 and 57 patients recruited to date.

- *Commercial Research Income – Quarters 1-2*
 - Invoices based on contracted research activity £543,096

At month 5 there were approx. £276k worth of bad debt (outstanding invoices over 90 days) for completed research activity. One Haematology study (MAIA) accounts for £190k of this debt and is being actioned by the Trusts legal team.

Patient & Public Involvement

4.1 Publicity and Communication

- There continues to be an active Twitter account promoting research activity at RWT: [@RWTResearch](#)
- The R&D Directorate are working with the Trust Volunteer service to develop their PPI initiatives, including research ambassadors and participant feedback.
- The research participant survey is underway and will report during the next quarter.

5

Governance

As part of our on-going commitment to quality and performance, the R&D Directorate continues to review and support quality assurance in line with European and UK regulator standards.

5.1 External Inspections.

- For the period of 1st April 2019 to 30th September 2019, 192 monitoring site visits have been conducted by study sponsors.

5.2 Annual Audit Programme

10 audits have been completed up to end September 19, one fewer than as per audit plan.

	Total
Delegation Log Audit	1
Consent Audit	0
External Access to Clinical Portal	6
Trust Sponsored Study	1
Study Amendments Audit	1
Out of Hours Process	0
Monitor Reports Audit	1
	10

Audit results are reported to the R&D Directorate Governance meeting and action plans agreed as necessary.

6

Awards and Commendations

The Trust has been recognised by commercial and non-commercial research sponsors for ranking highest in the UK for recruitment into studies in the following specialties:

- Oncology
- Cardiology
- Rheumatology
- Paediatrics
- Ophthalmology

The Trust has been nominated in 2 categories for the CRN WM Annual Awards, to be held in November 2019. The shortlisted nominees are -

- Emergency Department Team, including Paediatrics.
- The Royal Wolverhampton NHS Trust (CRN WM special category)

	<p>The oncology team have achieved notable success recently in 2 commercial studies. Both looking at treatments for Prostrate Cancer, one achieved 1st site to open in the UK and the second achieved 1st patient recruited outside the US (2nd Global recruit).</p>
--	---


Appendices	
1	Trust Sponsored Research Activity – Grant Awards
2	Research Activity by specialty

Appendix 1: Trust Sponsored Research Activity – Grant Awards.

Study Name	CI	Specialty	Grant Award	Grant Value	Portfolio Adopted?
Faecal bile acid study	Prof M Brookes	Gastroenterology	Bowel & Cancer Research	£36,755	Yes
			Tillots Pharma	£90,000	
Assessment of plasma and urine NGAL for the early prediction of acute kidney injury after cardiac surgery in adults	Prof R Gama	Clinical Chemistry / Cardiovascular	Rotha Abraham	£31,177	Yes
Optimising neonatal service provision for preterm babies (27-31 weeks)	Prof T Pillay	Neonatal	NIHR NSETSCC	£924,468	Yes
Biomarkers in pregnant inflammatory bowel disease patients	Prof H Steed	Gastroenterology	Tripartite	£40,000	Yes
Cardiac microRNA miR-1	Prof J Cotton	Cardiology	Rotha Abraham	£26,006	Yes
Metabolic syndrome and cancer	Dr S Menon	Gastroenterology	Rotha Abraham	£7,000	No
The efficacy and outcomes of cognitive screening and impact on dementia diagnosis in patients aged 75 and older admitted to hospital for emergency unplanned care	J Willoughby (RGN)	Dementia	Rotha Abraham	£24,827	No
Inflammatory Bowel Disease in pregnancy	Prof M Brookes	Gastroenterology	Crohn's and Colitis UK	£72,653	Yes
Iron deficiency anaemia in pregnancy	Prof D Churchill	Obs & Gynae	Rotha Abraham	£27,000	Yes
			NHS Blood & Transport	£25,000	

Appendix 2: Research Activity by Specialty.

RWT Portfolio Recruitment 2019/20 by Specialty



Notes

Cancer includes Haematological Cancers

Active Study Principle Investigators by Specialty

Specialty	Number of active PIs
Oncology	19
Cardiology	7
Paediatrics	11
Critical Care	2
Dementias and Neurodegeneration	1
Dermatology	3
Diabetes	4
ENT	1
Gastroenterology	3
Genetics	1
Haematology	2
Health services and delivery research	5
Hepatology	2
Infectious diseases and microbiology	2
Injuries and emergencies	3
Mental Health	1
Metabolic and endocrine disorders	1
Musculoskeletal disorders	9
Neurological disorders	1
Ophthalmology	4
Oral and Dental Health	1
Public Health	1
Renal disorders	5
Reproductive health and childbirth	4
Respiratory disorders	4
Stroke	2
Surgery	4